sector medic suppli devic
creat bluematrix
 earli read result
messag report mix result sale miss
consensu adjust ep cc beat organ
revenu growth certainli disappoint view manag cite
number transient issu weak bless street consensu
exclud potenti coronaviru impact earli quantifi combin
fact bullish call predic top-lin acceler
alway expect trough quarter growth expect neg
reaction shortfal somewhat mitig
top-lin stumbl three four busi fall short
expect third quarter organ revenu growth came wors
forecast manag guidanc downsid rel
consensu widespread cvg mitg rtg miss
diabet busi beat street expect quarter
cvg growth sequenti fell short guidanc
growth coronari structur heart cc came street
cardiac rhythm heart failur cc miss aortic peripher sale grew
cc come essenti line consensu csh tavr franchis
grew mid-teen ww estim tavr market overal
 heart failur weak chalk on-going stabil lvad headwind
custom await sever new product launch off-set high-single-
digit growth pacemak includ growth micra mid-single-digit
growth reveal linq meanwhil high-single-digit taa growth partial off-set
ww declin dcb
elsewher rtg mitg weak diabet top expect
rtg beat brain therapi off-set weak
pain therapi cc spine organ specialti therapi
cc highlight strong sale hemorrhag ischem
stroke portfolio well advanc navig driver brain therapi group
manag blame market slowdown slight share loss market
weak pain custom buy pattern neg impact infus
sale weigh spine combin drove organ growth rtg overal
vs manag guidanc turn mitg surgic innov
cc respiratori gastrointestin renal cc came
consensu drive cc growth mitg vs expect growth
manag attribut weak erp upgrad implement result
suppli constraint quarter issu fulli resolv final diabet sale
cc came ahead street strong intern growth cc
off-set low-double-digit declin
incom statement strong margin leverag off-set top-lin shortfal
drive ep beat gross margin came yoy
consensu meanwhil sg expens yoy sale
 spend sale overal ebita margin expand
yoy better street forecast elsewher tax rate
came consensu combin lower interest expens
add earn
back result manag maintain revenu outlook
rais ep continu expect revenu grow cc full
year organ growth expect meanwhil compani expect ep
cc compar current consensu
forecast
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst whose name appear report receiv compens base upon variou factor includ qualiti research
investor client feedback guggenheim secur llc overal revenu includ invest bank revenu
plc period preced date distribut report client guggenheim secur llc guggenheim
guggenheim secur llc affili receiv compens plc past month product servic invest
guggenheim secur llc affili expect receiv intend seek compens invest bank servic plc
next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori medtron plc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
page analyst certif import disclosur
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
equiti valuat risk valuat methodolog risk associ cover compani price target cover compani pleas
see recent company-specif research report http //guggenheimlibrari bluematrix com/client/librari jsp contact primari analyst
guggenheim secur llc repres email
research client prospect client disclosur relat guggenheim secur affili research
